279 related articles for article (PubMed ID: 16088931)
1. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
Martinez SR; Hoon DS
J Cell Biochem; 2005 Oct; 96(3):473-83. PubMed ID: 16088931
[TBL] [Abstract][Full Text] [Related]
2. Molecular staging for patients with malignant melanoma.
Shivers S; Jakub J; Pendas S; Reintgen D
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1665-74. PubMed ID: 18020932
[TBL] [Abstract][Full Text] [Related]
3. [The latest diagnostical methods and therapy in melanoma].
Wojas-Pelc A; Rajzer L; Jaworek A; Woźniak W
Przegl Lek; 2006; 63(8):674-80. PubMed ID: 17441381
[TBL] [Abstract][Full Text] [Related]
4. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
5. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients.
Mangas C; Hilari JM; Paradelo C; Rex J; Fernández-Figueras MT; Fraile M; Alastrue A; Ferrándiz C
Ann Surg Oncol; 2006 Jul; 13(7):910-8. PubMed ID: 16788751
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
9. Molecular upstaging of sentinel lymph nodes in melanoma: where are we now?
Martinez SR; Mori T; Hoon DS
Surg Oncol Clin N Am; 2006 Apr; 15(2):331-40. PubMed ID: 16632218
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
11. Malignant melanoma.
Califano J; Nance M
Facial Plast Surg Clin North Am; 2009 Aug; 17(3):337-48. PubMed ID: 19698915
[TBL] [Abstract][Full Text] [Related]
12. Predicting clinical outcome through molecular profiling in stage III melanoma.
John T; Black MA; Toro TT; Leader D; Gedye CA; Davis ID; Guilford PJ; Cebon JS
Clin Cancer Res; 2008 Aug; 14(16):5173-80. PubMed ID: 18698035
[TBL] [Abstract][Full Text] [Related]
13. Pitfalls in the use of rt-PCR as a prognostic indicator in melanoma.
Wascher RA
J Clin Oncol; 2005 Jun; 23(16):3863-4; author reply 3864-5. PubMed ID: 15923590
[No Abstract] [Full Text] [Related]
14. [Prognostic significance of some markers in cutaneous melanoma treated with different therapeutic modalities].
Nepomniashchaia EM; Gusareva MA; Petrov SV
Vopr Onkol; 2008; 54(6):744-8. PubMed ID: 19241851
[TBL] [Abstract][Full Text] [Related]
15. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
Harpio R; Einarsson R
Clin Biochem; 2004 Jul; 37(7):512-8. PubMed ID: 15234232
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
Quaglino P; Osella-Abate S; Cappello N; Ortoncelli M; Nardò T; Fierro MT; Cavallo F; Savoia P; Bernengo MG
Melanoma Res; 2007 Apr; 17(2):75-82. PubMed ID: 17496782
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis, treatment and follow-up of primary malignant skin melanoma].
Ketterer R
Rev Med Suisse Romande; 1995 Oct; 115(10):753-7. PubMed ID: 7501925
[No Abstract] [Full Text] [Related]
19. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
20. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection.
Rutkowski P; Nowecki ZI; Kulik J; Ruka W; Siedlecki JA
Melanoma Res; 2008 Aug; 18(4):246-52. PubMed ID: 18626308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
